Why the study?
Do xanthines inhibit human platelet aggregation induced by platelet-activating factor?
Do xanthines inhibit human platelet aggregation induced by platelet-activating factor?
Although xanthines inhibit PAF-induced platelet aggregation in vitro, therapeutic concentrations are unlikely to produce this effect in clinical settings.
Answers are grounded in this paper and cite their sources.
Unlikely to inhibit PAF effects at therapeutic levels; leaves open whether more potent analogs merit targeted investigation.
Platelet-activating factor (PAF) may be involved in the pathogenesis of asthma, and therefore the effects of the anti-asthma drugs theophylline and enprofylline on human platelet aggregation and adenosine triphosphate (ATP) release induced by PAF and adenosine diphosphate (ADP) were studied. 2. Enprofylline (50% inhibitory concentration [IC50] = 94.8 +/- 13.2 mumol/L) was more potent than theophylline (IC50 = 934.1 +/- 40.1 mumol/L) as an inhibitor of PAF-induced aggregation, and the xanthines were twice as potent as inhibitors of PAF-induced aggregation when compared with ADP-induced aggregation. ATP release was 1.4 times more sensitive to inhibition by the xanthines than aggregation. 3. Although high concentrations of xanthines inhibited platelet aggregation and ATP release induced by PAF, therapeutic concentrations are unlikely to inhibit PAF-induced effects.
No takes yet. Share an insight, caveat, or question.
Misso et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: